EC Number   |
Natural Substrates |
|---|
   1.11.1.20 | prostaglandin H2 + reduced thioredoxin |
- |
| 1.11.1.20 | prostamide F2alpha + oxidized thioredoxin |
- |
| 1.11.1.20 | prostamide H2 + reduced thioredoxin |
- |
| 1.11.1.20 | thioredoxin + (5Z)-N-(2-hydroxyethyl)-7-[(1R,4S,5R,6R)-6-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-2,3-dioxabicyclo[2.2.1]hept-5-yl]hept-5-enamide |
(5Z)-N-(2-hydroxyethyl)-7-[(1R,4S,5R,6R)-6-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-2,3-dioxabicyclo[2.2.1]hept-5-yl]hept-5-enamide i.e. prostamide H2. The product of the reaction prostamide F2alpha is a COX-2-catalyzed metabolite of arachidonoyl ethanolamide that induces important pharmacological actions via interaction with a putative prostamide receptor |
| 1.11.1.20 | thioredoxin + (5Z,9alpha,11alpha,13E,15S)-9,11-epidioxy-15-hydroxy-prosta-5,13-dienoate |
(5Z,9alpha,11alpha,13E,15S)-9,11-epidioxy-15-hydroxy-prosta-5,13-dienoate i.e. prostaglandin H2. The product of the reaction prostaglandin F2alpha induces luteolysis in the estrous cycle and plays essential roles in parturition with its strong uterine contractile actions and has vasoconstriction and bronchoconstriction activities. PGF2alpha exerts these biological functions by binding to the FP receptor, a G-protein-coupled receptor that signals through Gq-mediated increases in intracellular calcium |
| 1.11.1.20 | thioredoxin + (5Z,9alpha,11alpha,13E,15S)-9,11-epidioxy-15-hydroxy-prosta-5,13-dienoate |
i.e. prostamide H2 |
| 1.11.1.20 | thioredoxin + prostaglandin H2 |
- |
| 1.11.1.20 | thioredoxin + prostamide H2 |
- |
